Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G, D'Aiuto G, Comella P, Apicella A, Thomas R, Capasso I, Di Bonito M, Cartenì G, Biglietto M, De Lucia L, Maiorino L, Piccolo S, Bianchi U, D'Aniello R, Lapenta L, Comella G. Frasci G, et al. Breast Cancer Res Treat. 1999 Aug;56(3):239-52. doi: 10.1023/a:1006263226099. Breast Cancer Res Treat. 1999. PMID: 10573115 Clinical Trial.
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Frasci G, Comella P, D'Aiuto G, Thomas R, Capasso I, Elmo M, Botti G, Cortino GR, Lapenta L, De Rosa V, Vallone P, Petrillo A, Comella G. Frasci G, et al. Ann Oncol. 2000 Mar;11(3):367-71. doi: 10.1023/a:1008346708604. Ann Oncol. 2000. PMID: 10811508 Free article. Clinical Trial.
Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
Frasci G, D'Aiuto G, Comella P, Thomas R, Capasso I, Di Bonito M, Rivellini F, Carteni G, De Lucia L, Maiorino L, D'Aniello R, Frezza P, Lapenta L, Comella G. Frasci G, et al. Breast Cancer Res Treat. 2000 Jul;62(2):87-97. doi: 10.1023/a:1006429205363. Breast Cancer Res Treat. 2000. PMID: 11016746 Clinical Trial.
Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study.
Frasci G, D'Aiuto G, Comella P, Thomas R, Capasso I, Botti G, Cortino GR, De Rosa V, Comella G; Southern Italy Cooperative Oncology Group; National Tumor Institute of Naples. Frasci G, et al. Semin Oncol. 2001 Jun;28(3 Suppl 10):50-6. doi: 10.1053/sonc.2001.22533. Semin Oncol. 2001. PMID: 11510034 Clinical Trial.
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Frasci G, D'Aiuto G, Comella P, Thomas R, Botti G, Di Bonito M, De Rosa V, Iodice G, Rubulotta MR, Comella G; Southern Italy Cooperative Oncology Group (SICOG). Frasci G, et al. Br J Cancer. 2006 Oct 23;95(8):1005-12. doi: 10.1038/sj.bjc.6603395. Br J Cancer. 2006. PMID: 17047649 Free PMC article. Clinical Trial.
92 results